Jefferies Starts Agenus Inc. (AGEN) at Buy; Sees 100% Upside
December 16, 2015 7:54 AM EST
Jefferies initiates coverage on Agenus Inc. with a Buy rating and a price target of $8.00.
Analyst Biren Amin commented,
"Agenus is developing a comprehensive Immuno-Oncology (IO) platform consisting of multiple checkpoints both fully owned and through partnerships and could be a leader in cancer vaccine development through the deployment of its QS-21 adjuvant which could increase the efficacy of cancer vaccines. AGEN is also partnered with Merck and Incyte across 9 novel IO programs totaling >$450M in milestones. Therefore, AGEN's $130M EV offers significant upside, in our view."
Learn my "Core and Explore" approach to investing
with "Kirk Lindstrom's Investment Letter"
Don't miss out! Subscribe Now
so your risk is minimal
More articles:
- Dec 10 6
Weekly Sentiment Charts - Was It A Bloody Gash Or A Cut?
- Nov 3 New Series I Bonds Offer Attractive Rates
- Oct 15 2016 Social Security COLA: Cost-of-Living Adjustment (COLA) for 2016
- Sept 2 Good News for Intel Stock - End of Inventory Correction
No comments:
Post a Comment